Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461
Public ClinicalTrials.gov record NCT02329184. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Safety, Tolerability, Preliminary Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of MYK-461 in Patient Volunteers With Hypertrophic Cardiomyopathy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to establish initial safety, tolerability, pharmacokinetics and pharmacodynamics of MYK-461 in human subjects. This is a sequential group, single ascending (oral) dose study in NYHA Class I, II, or III patient volunteers aged 18-65 years.
Study identification
- NCT ID
- NCT02329184
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 15 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2014
- Primary completion
- Feb 29, 2016
- Completion
- Mar 31, 2016
- Last update posted
- Sep 13, 2016
2014 – 2016
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Scottsdale | Arizona | 85259 | — |
| Not listed | Cypress | California | 90630 | — |
| Not listed | Stanford | California | 94305 | — |
| Not listed | Boston | Massachusetts | 02111 | — |
| Not listed | Kalamazoo | Michigan | 49007 | — |
| Not listed | Durham | North Carolina | 27710 | — |
| Not listed | Nashville | Tennessee | 37232 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Hypertrophic Cardiomyopathy trials
Other public records listing Hypertrophic Cardiomyopathy. Sorted by last update posted; newest first. Not a recommendation.
- NCT06290570: A Study of Artificial Intelligence ECG With ECG Devices to Detect Hypertrophic Cardiomyopathy Distinct From Athlete's Active, not recruiting
- NCT05836259: Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM Recruiting
- NCT06347159: A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM) Active, not recruiting
- NCT05818605: Exercise Intolerance in Non-obstructive Hypertrophic Cardiomyopathy Recruiting
- NCT05939700: Mavacamten Pregnancy Surveillance Program Recruiting
- NCT07103057: VIZ ACCESS HCM - Multi-Site Registry Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02329184, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 13, 2016 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02329184 live on ClinicalTrials.gov.